Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Implanet logo — The permanent balance

Implanet

The permanent balance

Founded 2007 France France 43 employees Post-IPO Debt Total: $69.82M Biotechnology, Health Care +1

General Information

Company Name Implanet
Founded Year 2007
Location France France
Founders / Decision Makers
Team member
Employees 43
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Implanet. To contact Implanet, visit implanet.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Implanet compare?

A PDF of Implanet and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Implanet soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Implanet

Implanet, based near Bordeaux (FR), is an international company with a US subsidiary in Boston, founded in 2007. The company focuses on spine and knee products and is funded by European institutional and private investors. Their flagship product, Jazz™, is designed to improve the treatment of spinal disorders requiring spinal fusion surgery and has obtained 510(k) clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. Implanet's Marketing team identifies a portfolio of products and services based on a detailed analysis of socio-economic, regulatory, demographic, and cultural specifications, while the R&D team focuses on scientifically and clinically proven implant design. Implanet's last investment of €2.00M post-IPO debt was from Shanghai Pudong Development Bank on 05 December 2024. With a focus on providing high-quality products and services to adequately respond to healthcare professionals' requirements, Implanet aims to offer the best value for their products, needs, and demands.

Business keywords: Orthopedic implants, Medical devices, Spinal surgery, Implant design, Regulatory clearance, International patents, Surgical instruments, Healthcare professionals support, Global healthcare solutions

Services & Products

Development and manufacturing of innovative medical devices for spinal surgery and other surgical disciplines.

Target Customers

Healthcare professionals including surgeons hospitals and medical facilities.

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt €2.00M 1
Shanghai Pudong Development Bank
05 Dec 2024
Post IPO Equity $2.70M -
27 Oct 2022
Post IPO Equity €1.00M 1
Nice & Green SA
Nice & Green SA
09 Nov 2018
Series E €18.70M 1
Auriga Partners
Auriga Partners
01 Nov 2013
Series D €5.32M 1
Auriga Partners
Auriga Partners
01 Sep 2011
Series D $10.10M 3
Wellington Partners Andera Partner CM-CIC Capital Prive
Wellington Partners, Andera Partner +1
12 Jul 2010
Series C €8.00M 5
Seventure Partners Auriga Partners Wellington Partners
Seventure Partners, Auriga Partners +3
20 Apr 2010
Series B €9.00M 4
Seventure Partners Auriga Partners Wellington Partners
Seventure Partners, Auriga Partners +2
30 Jun 2009
Series A €13.00M 3
Auriga Partners Wellington Partners Andera Partner
Auriga Partners, Wellington Partners +1
01 May 2007

Implanet Alternatives & Competitors

View All Alternatives
Implanet vs
Innovasis, Inc.
Innovasis, Inc. United States

Innovate / Involve / Invent

47 employees
Biotechnology, Health Care
Implanet vs
CoreLink Surgical
CoreLink Surgical United States

We design, manufacture, and distribute surgical implants and instruments for spinal fusion procedure...

Venture round
22 employees
Design, Health Care
Compare Implanet vs CoreLink Surgical
Implanet vs
Sonoma Orthopedics
Sonoma Orthopedics

The innovative technology platform offers swift, minimally invasive surgical solutions for active in...

Venture round
1 employees
Biotechnology, Health Care
View all alternatives

FAQ About Implanet

The permanent balance
Implanet was founded in 2007.
Implanet is headquartered in France.
Implanet operates in Biotechnology, Health Care and Medical Devices. Its work centres on Orthopedic implants, Medical devices, Spinal surgery and Implant design. Its customers include Healthcare professionals, including surgeons and hospitals.
Implanet has approximately 43 employees.
Implanet has completed 9 funding rounds, raising a total of $69.82M. The latest funding stage is Post-IPO Debt.
Implanet offers: Development and manufacturing of innovative medical devices for spinal surgery and other surgical disciplines..
Top alternatives and competitors to Implanet include Innovasis, Inc., CoreLink Surgical, Sonoma Orthopedics, Ellipse Technologies, Inc., New Age Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Implanet and Innovasis, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Implanet, https://bouncewatch.com/company/implanet, updated 11 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes